CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that collaborating investigators from ARIAD, the Howard Hughes Medical Institute and the Oregon Health and Science University will present data from preclinical studies on AP24534, ARIAD’s multi-targeted kinase inhibitor, at the 49th Annual Meeting of the American Society of Hematology in Atlanta, Georgia, December 8 to 11, 2007.
“These preclinical findings illustrate the progress we have made over the past year with AP24534 – a novel multi-targeted kinase inhibitor discovered and characterized by ARIAD scientists. We look forward to sharing these new findings with the scientific community at ASH,” said Timothy P. Clackson, Ph.D., senior vice president and chief scientific officer of ARIAD.
